Taken together, these findings pave the way for the discovery of sEV‐associated biomarkers for Syntenin‐overexpressing cancers and may help to unravel molecular mechanisms behind specific pathological functions of tumour‐derived sEVs. Here, SDCBP is linked to neoplasm.